MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster ...

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

EMA's human medicines committee issued positive recommendations for multiple drugs, including Merck's Keytruda and InflaRx's ...

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at ...

Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression aft ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning ladies and gentlemen and welcome to PDS Biotech’s Third Quarter 2024 Results and Clinical Strategy Update Conference Call. All ...

The U.S. Food and Drug Administration approved the Keytruda combination in malignant pleural mesothelioma in September. Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors ...

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose ...

Bridgemarq Real Estate Services Inc. ("Bridgemarq" or the "Company") today released its third quarter consolidated financial results and announced a monthly dividend to holders of the Company's ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

Vibostolimab/Keytruda regimen did not improve overall survival compared to Tecentriq in extensive-stage SCLC patients. Median ...